(Date:11/20/2009)...have an opportunity to take the lead in two small ...sity of Valencia (UV), working together with the I...ric of the Spanish biotechnology industry. Their c...ave more clout than those in English-speaking coun...ants has been overlooked by the leading countries ...
(Date:11/20/2009)...wswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)...inth Circuit Court of Appeals reversed a U.S. Dist...wed to pursue all of its claims against The Lash G...for trial. CTI filed a complaint against The Lash...sultant for CTI,s product TRISENOX, in 2007 seekin...
(Date:11/19/2009)...re-FirstCall/ -- Omeros Corporation (Nasdaq: OMER... the third quarter ended September 30, 2009. For t...eported a net loss of $3.9 million, or $1.34 per s...r $2.54 per share, for the same period in 2008. Fo...mpany reported a net loss of $15.5 million, or $5....
(Date:11/19/2009)...AM, Mass., Nov. 19 Arlington Medic...t the leading driver of antibiotic selection in no...ivity against gram-positive and gram-negative path...use nosocomial pneumonia, surveyed European physic...at provide appropriate coverage against common pat...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3...rned another national mention as a "biotech hotspo...In aggregate this kind of recognition raises the s...ry has been asking for. , ,Joining Wisconsin on th... New Jersey and Singapore. John Carroll, the edito...it was a subjective ranking based on "chemistry as...
... GE Healthcare Technologies in Waukesha has a ne...ief executive Reinoldo Garcia will be moving on to..., ,Mark Vachon, who was executive vice president a...CEO. He has held many roles with the company, incl...subsidiary. , , GE Healthcare is a far-flung comp...
...ation Center Back in the mid-1980s, encouraging e...st Wisconsin public utilities. But then Plant Site...h business concentrations across the U.S. , ,Jim ...adison Gas & Electric, saw the article and mention... County had more high-tech development than the ma...
Other Biology Technology:Utilities help switch on economic development 2Utilities help switch on economic development 3Utilities help switch on economic development 4...ked to protein G-agarose beads which can immunocap... Also included are 2 mg of bovine heart mitochondr...rogenase complex (PDH) immunocapture kit allows is...facilitates the subsequent analysis of the assembl...
...uperior to transfection in some applications. For...LSin you can study lethal proteins and control the...ise, delivery of blocking antibodies may provide m...experiments. ,With PULSin you can target intrac...
...uperior to transfection in some applications. For...LSin you can study lethal proteins and control the...ise, delivery of blocking antibodies may provide m...experiments. ,With PULSin you can target intrac...
...s the superior cell-sorting instrument for the res...rs have been the gold standard and are found in le...y research facilities throughout the world. To me... the BD FACS VantageTM and added options that cust...
Biology Products: